123 related articles for article (PubMed ID: 1386817)
1. The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month.
Hackenberg R; Gesenhues T; Deichert U; Duda V; Schmidt-Rhode P; Schulz KD
Eur J Obstet Gynecol Reprod Biol; 1992 Jul; 45(2):125-9. PubMed ID: 1386817
[TBL] [Abstract][Full Text] [Related]
2. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
Hackenberg R; Gesenhues T; Deichert U; Duda V; Sturm G; Schulz KD
Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
[TBL] [Abstract][Full Text] [Related]
3. Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
McClelland HR; Quinn AJ
Ulster Med J; 1992 Apr; 61(1):51-5. PubMed ID: 1535743
[TBL] [Abstract][Full Text] [Related]
4. The short-term use of luteinising hormone-releasing hormone analogues in uterine fibroids.
Van der Spuy ZM; Fieggan AG; Wood MJ; Pienaar CA
Horm Res; 1989; 32 Suppl 1():137-40. PubMed ID: 2533144
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of LHRH analogue action in uterine fibroids.
Shaw RW
Horm Res; 1989; 32 Suppl 1():150-3. PubMed ID: 2533145
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
Matta WH; Shaw RW; Nye M
Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
[TBL] [Abstract][Full Text] [Related]
7. The management of leiomyoma uteri by GnRH analogues.
Giorgino FL; Cetera C
Clin Exp Obstet Gynecol; 1991; 18(2):137-43. PubMed ID: 1833095
[TBL] [Abstract][Full Text] [Related]
8. [GnRH-analogs in the therapy of uterine myomatosis].
Wieacker P; Geisthövel F; Adelberger V; Breckwoldt M
Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
[TBL] [Abstract][Full Text] [Related]
9. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
West CP; Lumsden MA; Lawson S; Williamson J; Baird DT
Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863
[TBL] [Abstract][Full Text] [Related]
10. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
[TBL] [Abstract][Full Text] [Related]
11. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L
Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical localization of epidermal growth factor receptor in leiomyomas from women treated with goserelin depot.
Leone M; Cucuccio S; Venturini PL; Valenzano-Menada M; Messeni Leone M; De Cecco L
Horm Metab Res; 1991 Sep; 23(9):442-5. PubMed ID: 1835956
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
[TBL] [Abstract][Full Text] [Related]
14. Treatment of peri-menopausal women: potential long-term therapy with a depot GnRH agonist combined with hormonal replacement therapy.
Maheux R; Lemay A
Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():13-7. PubMed ID: 1532506
[No Abstract] [Full Text] [Related]
15. Goserelin (Zoladex) in the treatment of fibroids.
West CP; Lumsden MA; Baird DT
Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():27-30. PubMed ID: 1532507
[No Abstract] [Full Text] [Related]
16. Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women.
Vollenhoven BJ; Shekleton P; McDonald J; Healy DL
Fertil Steril; 1990 Dec; 54(6):1032-8. PubMed ID: 2123160
[TBL] [Abstract][Full Text] [Related]
17. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
[TBL] [Abstract][Full Text] [Related]
18. The binding of steroids to myometrium and leiomyomata (fibroids) in women treated with the gonadotrophin-releasing hormone agonist Zoladex (ICI 118630).
Lumsden MA; West CP; Hawkins RA; Bramley TA; Rumgay L; Baird DT
J Endocrinol; 1989 May; 121(2):389-96. PubMed ID: 2526844
[TBL] [Abstract][Full Text] [Related]
19. [New possibilities for differentiated therapy of leiomyoma of the uterus using the GnRH agonist zoladex].
Gesenhues T; Hackenberg R; Diechert U; Duda V; Sturm G; Schulz KD
Geburtshilfe Frauenheilkd; 1989 Feb; 49 Suppl 1():96-8. PubMed ID: 2522904
[TBL] [Abstract][Full Text] [Related]
20. Transient shrinkage of a uterine leiomyosarcoma treated with GnRH agonist for a presumed uterine leiomyoma: comparison of magnetic resonance imaging finding before and during GnRH agonist treatment.
Kawamura N; Iwanaga N; Hada S; Maeda K; Sumi T; Ishiko O; Ogita S
Oncol Rep; 2001; 8(6):1255-7. PubMed ID: 11605044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
